A detailed history of Natixis transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Natixis holds 1 shares of DVAX stock, worth $12. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1
Previous 1,667 99.94%
Holding current value
$12
Previous $18,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$10.05 - $11.61 $16,743 - $19,342
-1,666 Reduced 99.94%
1 $0
Q2 2024

Aug 13, 2024

BUY
$10.73 - $12.58 $17,886 - $20,970
1,667 New
1,667 $18,000
Q2 2022

Aug 12, 2022

BUY
$7.45 - $12.83 $452,960 - $780,064
60,800 New
60,800 $765,000
Q4 2017

Feb 14, 2018

SELL
$17.3 - $24.08 $269,585 - $375,238
-15,583 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$15.2 - $21.5 $236,861 - $335,034
15,583
15,583 $335,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.62B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Natixis Portfolio

Follow Natixis and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

News

Stay updated on Natixis with notifications on news.